Table 3.
Neoadjuvant chemotherapy followed by chemoradiation in locally advanced rectal cancer.
| Study Regimen | N | int(w) | SPS | pCR | DFS | OS | |||
|---|---|---|---|---|---|---|---|---|---|
| Neoadjuvant | CRT | Adjuvant | |||||||
| Chau et al. [100] | 5-FU, MMC (7) | 50.4 Gy with 5-FU | 5-FU, MMC (7) | 36 | 6 | 56% | 3% | 1 y: 72.1% | 2 y: 70.3% |
| EXPERT [101] | CAP (1000), OX (130) | 54 Gy with CAP (825) | CAP (1250) | 105 | 6 | 63% | 20% | 3 y: 68% | 3 y: 83% |
| GCR3 [94] | — | 50.4 Gy with CAP (825) | CAP (2000), OX (130) | 52 | 5-6 | — | 13% | 1.5 y: 82% | 1.5 y: 89% |
| CAP (2000), OX (130) | 50.4 Gy with CAP (825) | — | 56 | 5-6 | — | 14% | 1.5 y: 76% | 1.5 y: 91% | |
| BGDO [95] | — | 45 Gy with 5-FU CIV | — | 29 | 6–8 | 67% | 27% | — | — |
| 5-FU, OX (100) | 45 Gy with 5-FU CIV | — | 28 | 6–8 | 100% | 25% | — | — | |
| Schou et al. [102] | CAP(2000), OX (130) | 54 Gy + CAP (1650) | None | 84 | 6 | — | 25% | 5 y: 63% | 5 y: 67% |
| AVACROSS [96] | CAP (1000), OX (130), bev | 45 Gy + CAP (825) + bev | CAP + OX | 47 | 6–8 | 60% | 36% | — | — |
| Dipetrillo et al. [83] | 5-FU, OX (85), bev | 50.4 Gy + OX (50) + bev | 5-FU + OX + bev | 26 | 4–8 | 76% | 20% | 4 y: 65% | 4 y: 96% |
| EXPERT-C [78] | CAP (1700), OX (130) | 50.4 Gy + CAP (1650) | CAP + OX | 81 | 4–6 | 73% | 15% | HR: 0.3–2.16 | HR: 0.07–0.99 |
| CAP (1700), OX (130), cet | 50.4 Gy + CAP (1650) + cet | CAP + OX + cet | 84 | 4–6 | 73% | 14% | |||
CAP: capecitabine; MMC: mitomycin C; OX: oxaliplatin; cet: cetuximab; bev: bevacizumab; RT: radiotherapy; pCR: pathological complete response; SPS: sphincter preserving surgery; OS: overall survival; DFS: disease free survival; int: interval in weeks.